The extracellular signal-regulated kinase (ERK) pathway: a potential therapeutic target in hypertension

Richard E Roberts
School of Biomedical Sciences, University of Nottingham, Nottingham, United Kingdom

Abstract: Hypertension is a risk factor for myocardial infarction, stroke, renal failure, heart failure, and peripheral vascular disease. One feature of hypertension is a hyperresponsiveness to contractile agents, and inhibition of vasoconstriction forms the basis of some of the treatments for hypertension. Hypertension is also associated with an increase in the growth and proliferation of vascular smooth muscle cells, which can lead to a thickening of the smooth muscle layer of the blood vessels and a reduction in lumen diameter. Targeting both the enhanced contractile responses, and the increased vascular smooth muscle cell growth could potentially be an important pharmacological treatment of hypertension. Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated protein kinase family that is involved in both vasoconstriction and vascular smooth muscle cell growth and this, therefore, makes it an attractive therapeutic target for treatment of hypertension. ERK activity is raised in vascular smooth muscle cells from animal models of hypertension, and inhibition of ERK activation reduces both vascular smooth muscle cell growth and vasoconstriction. This review discusses the potential for targeting ERK activity in the treatment of hypertension.

Keywords: ERK, hypertension, smooth muscle, vasoconstriction

Introduction

Hypertension is a risk factor for myocardial infarction, stroke, renal failure, heart failure, and peripheral vascular disease. It is associated with both enhanced responses to contractile agents, and an increase in the growth and proliferation of vascular smooth muscle cells. The protein kinase extracellular signal-regulated kinase (ERK) is involved in both vasoconstriction and vascular smooth muscle cell growth and this, therefore, makes it an attractive target for the treatment of hypertension.

The mitogen-activated protein kinase (MAPK) family of enzymes include the ERKs (ERK1, ERK2, ERK3/4, ERK5, ERK7), the c-Jun amino-terminal kinases, and p38 MAPKs. Common to all of the MAPK family of protein kinases is activation via a sequential phosphorylation cascade, made up of three protein kinases: MAPK kinase (MEK) kinase, MEK, and MAPK (Figure 1). ERK1 and ERK2 are activated through the Ras/Raf/MEK cascade. Activation of the heterotrimeric G protein Ras leads to activation of the MEK kinase Raf, which in turn activates MEK, which then phosphorylates ERK1 and ERK2 at threonine 202 and tyrosine 204 to activate the enzymes.

Although other isozymes of ERK are known, ERK1 and ERK2 are the most studied. This review will concentrate on these two isozymes. Phosphorylated ERK1 and ERK2 enter the nucleus where they themselves phosphorylate transcription factors...
factors involved in regulation of the cell-cycle and tissue proliferation. In differentiated, contractile vascular smooth muscle, ERK1 and ERK2 in the cytoplasm are involved in the regulation of vascular smooth muscle contraction. As far as this review is concerned, ERK refers to ERK1 and ERK2.

ERK can be activated through stimulation of G protein-coupled receptors (GPCRs) and release of Gβγ subunits, or through activation of growth factor-stimulated tyrosine kinase receptors (Figure 2). As well as activation by Gβγ subunits after stimulation of GPCRs, ERK can also be activated through transactivation of growth factor tyrosine kinase receptors such as the epidermal growth factor (EGF) receptor, involving either tyrosine phosphorylation of the receptor, or the proteolytic cleavage of a membrane bound ligand, which then activates the receptor (Figure 2).

### Role of ERK in regulation of vascular smooth muscle contraction

Hypertension is associated with an increase in the contraction of blood vessels in response to agonist stimulation, and impaired relaxation responses to both endothelium-dependent and -independent stimuli. Contraction of isolated blood vessels in response to activation of certain GPCRs is associated with an increase in ERK activity, and inhibition of ERK activation by inhibiting the upstream protein kinase MEK reduces contraction of blood vessels. Stretch-induced contractions are also associated with an increase in ERK activity. The relative role of ERK in the contractile response appears to depend upon the receptor activated and/or the blood vessel. For example, ERK appears to play a greater role in α2-adrenoceptor-mediated contractions in the porcine palmar lateral vein compared to α1-adrenoceptor-mediated contractions in the
ferret aorta.\textsuperscript{12,14} Currently, the mechanism by which ERK causes contraction of the blood vessels is not clear. One hypothesis is that ERK phosphorylates the actin-binding protein caldesmon (Figure 3). Caldesmon can inhibit the adenosine triphosphatase activity of actomyosin,\textsuperscript{16} and it has been proposed that phosphorylation of caldesmon by ERK removes this inhibitory effect. Phosphorylation of caldesmon at serine 789 by ERK is thought to bring about a conformational change in caldesmon,\textsuperscript{17} resulting in decreased binding to actin and, hence, removal of the adenosine triphosphatase inhibition.\textsuperscript{18} Caldesmon phosphorylation that is inhibited by the MEK inhibitor PD98059 has been shown to be associated with vasoconstriction,\textsuperscript{12,19} although other studies have suggested that ERK only phosphorylates \textit{l}-caldesmon, which is only present in dedifferentiated smooth muscle, and thus suggesting that ERK phosphorylation of caldesmon is involved in cell division rather than contraction.\textsuperscript{20} Phosphorylation of \textit{l}-caldesmon in dedifferentiated cells may regulate migration of proliferating vascular smooth muscle cells and, therefore, may play a role in the development of smooth muscle hyperplasia in hypertension.\textsuperscript{21} Other studies have found no correlation between caldesmon phosphorylation by ERK and blood vessel contraction, further questioning the role of caldesmon in the ERK-mediated contractile response.\textsuperscript{22–25}

Alternative mechanisms by which ERK mediates vasoconstriction include activation of myosin light-chain kinase, leading to increased phosphorylation of myosin light-chains and hence contraction.\textsuperscript{26} This is supported by studies in the porcine palmar lateral vein showing that inhibition of ERK activation causes a reduction in myosin light-chain phosphorylation.\textsuperscript{27} Phosphorylated ERK has also been shown to be associated with the actin cytoskeleton,\textsuperscript{28} which could be related to phosphorylation of caldesmon or phosphorylation of myosin light-chains.

**Figure 3** Schematic diagram summarizing the potential mechanisms by which extracellular signal-regulated kinase could regulate vasoconstriction.

**Notes:** Phosphorylation of caldesmon at serine 789 is thought to inhibit the activity of this protein, thus removing its inhibitory effect on myosin adenosine triphosphatase. Alternatively, extracellular signal-regulated kinase could activate myosin light-chain kinase leading to an increase in phosphorylation of the myosin light-chains.

**Abbreviations:** ATPase, adenosine triphosphatase; ERK, extracellular signal-regulated kinase; MLC, myosin light-chain; MLCK, myosin light-chain kinase; MLC-P, myosin light-chain phosphorytase.

---

**Role of ERK in regulation of vascular smooth muscle growth**

Abnormal growth and proliferation of vascular smooth muscle cells, leading to a thickening of the smooth muscle cell layer and a reduction of the lumen diameter, is a major feature of hypertension, and may underlie the increase in the contractility of blood vessels.\textsuperscript{29} Activation of ERK is associated with changes in gene transcription and cell proliferation (Figure 4).\textsuperscript{3} In vascular smooth muscle, ERK is activated by growth factors, such as EGF, to regulate gene transcription and cell proliferation.\textsuperscript{5,30–32} Transactivation of the EGF receptor leading to activation of ERK has been shown to be involved in the induction of vascular smooth muscle cell growth after activation of \(\alpha_{\text{v}}\)-adrenoceptors.\textsuperscript{33} A similar transactivation of the EGF receptor is implicated in angiotensin II-induced vascular smooth muscle cell proliferation.\textsuperscript{34} These studies indicate the importance of ERK in the regulation of vascular smooth muscle cell proliferation. Indeed, modulation of primary vascular smooth muscle cells from a contractile to a proliferating phenotype is associated with prolonged ERK activation.\textsuperscript{35} This could be important in disease states such as hypertension and stenosis in which there are increases in vascular smooth muscle cell growth or remodeling (hyper trophy or hyperplasia).\textsuperscript{36,37}

Vascular smooth muscle cells exist in two phenotypes: a fully differentiated, contractile phenotype and a dedifferentiated, proliferating phenotype. During hyperplasia of the smooth muscle layer, dedifferentiation from a contractile phenotype back into a proliferating phenotype causes a loss of contractile function. Altering the regulation of ERK activation may be a way of changing the phenotype.
of vascular smooth muscle cells back to the contractile type, thus reducing smooth muscle proliferation. For example, in an ex vivo organ culture model of smooth muscle hyperplasia, both platelet-derived growth factor and endothelin-1 induced smooth muscle cell growth were prevented by inhibiting ERK activation and caused a partial restoration of the contractile response, indicating that therapeutic inhibition of ERK activation could prevent smooth muscle hyperplasia.

**Evidence for changes in ERK activity in hypertension**

Basal levels of ERK are raised in a number of different animal models of hypertension, including spontaneously hypertensive rats (SHRs), and agonist-stimulated ERK activation is also enhanced in vascular smooth muscle cells from SHRs. Inhibition of ERK activation inhibits the enhanced contraction to agonists seen in hypertension. For example, angiotensin II-mediated contraction of smooth muscle cells from SHRs is increased compared to normotensive controls, and this is normalized by inhibition of ERK activation. On the other hand, treatment of SHRs with MEK inhibitor PD98059 for 24 hours had no effect on blood pressure. Similarly, chronic treatment with PD98059 (24 weeks) did not reverse the increase in blood pressure in SHRs. On the other hand, inhibition of ERK activity was associated with an improvement of endothelial function, and angiotensin II-mediated vasoconstriction was inhibited after 24-hour treatment with PD98059. Structure of the blood vessels was unaltered by treatment with PD98059 after 24 hours, but this would be as expected in such a short time frame. In comparison, chronic (24 week) treatment with PD98059 caused a partial reduction in the thickening of the vascular wall in renal arteries from SHRs.

Although PD98059 had no effect on blood pressure in SHRs, in both deoxycorticosterone acetate salt-induced hypertension and angiotensin II-induced hypertension, treatment with PD98059 reduced blood pressure within 30–60 minutes, suggesting that the role of ERK in the regulation of blood pressure may depend on the animal model used.

**Role of reactive oxygen species in ERK activation in hypertension**

Hypertension is associated with an increase in the levels of reactive oxygen species in vascular smooth muscle cells, and this can be mediated by ERK activation. ERK can be activated through production of reactive oxygen species from both NADPH oxidase and mitochondria. Activated ERK mediates vascular smooth muscle contraction and could underlie the changes in vasoconstriction in hypertension. Activated ERK also causes changes in gene transcription leading to modulation of vascular smooth muscle phenotype and increases in vascular smooth muscle cell proliferation, which could underlie the hypertrophy/hyperplasia in hypertension.

**Abbreviations:** ERK, extracellular signal-regulated kinase; GPCR, G protein-coupled receptor; H$_2$O$_2$, hydrogen peroxide; MEK, mitogen-activated protein kinase kinase; NADPH, nicotinamide adenine dinucleotide phosphate; O$_2$, oxygen.

---

**Figure 5** Schematic diagram summarizing the role of extracellular signal-regulated kinase (ERK) in vascular smooth muscle and hypertension. Notes: ERK can be activated through either stimulation of G protein-coupled receptors or growth factor tyrosine kinase receptors. As well as direct activation of ERK through G protein-coupled receptors, G protein-coupled receptor-stimulated transactivation of growth factor receptors can also lead to ERK activation. ERK can also be activated through production of reactive oxygen species from both NADPH oxidase and mitochondria. Activated ERK mediates vascular smooth muscle contraction and could underlie the changes in vasoconstriction in hypertension. Activated ERK also causes changes in gene transcription leading to modulation of vascular smooth muscle phenotype and increases in vascular smooth muscle cell proliferation, which could underlie the hypertrophy/hyperplasia in hypertension. Abbreviations: ERK, extracellular signal-regulated kinase; GPCR, G protein-coupled receptor; H$_2$O$_2$, hydrogen peroxide; MEK, mitogen-activated protein kinase kinase; NADPH, nicotinamide adenine dinucleotide phosphate; O$_2$, oxygen.
from both mitochondria and nicotinamide adenine dinucleotide phosphate oxidase. This increase in reactive oxygen species may be responsible for the increase in ERK activity in hypertension (Figure 5). For example, hydrogen-peroxide increases ERK activation, which is more prominent in SHR compared to control animals. Furthermore, nicotinamide adenine dinucleotide phosphate oxidase activation and peroxide production can enhance vasoconstriction through activation of ERK. 5-hydroxytryptamine stimulation of ERK in bovine pulmonary artery smooth muscle cells is mediated through production of reactive oxygen species, which may be related to the ability of 5-hydroxytryptamine to enhance smooth muscle proliferation. Interestingly, production of reactive oxygen species has been linked to the transactivation of the EGF receptor leading to ERK-mediated vascular smooth muscle cell growth. Protein kinase C and calcium/calmodulin-dependent pathways have also been suggested to be involved in hydrogen peroxide-mediated ERK activation in vascular smooth muscle cells. Although reactive oxygen species have been reported to activate Ras in vascular smooth muscle cells, this did not appear to lead to ERK activation. Together, these data indicate that the increase in reactive oxygen species in hypertension may produce responses through the ERK pathway and that reactive oxygen species-stimulated ERK activation may be involved in both vasoconstriction and increases in smooth muscle proliferation.

**ERK as a therapeutic target in hypertension**

The studies highlighted in this review demonstrate that ERK plays a role in mediating vasoconstriction and vascular smooth muscle cell growth, and that there is an increase in ERK activity in hypertension. The fact that ERK plays a role in both vasoconstriction and smooth muscle growth makes it an attractive target for treatment of hypertension as inhibition of ERK activity would lead to a reduced contraction of the vascular smooth muscle and would also prevent the increase in smooth muscle cell growth seen in vascular smooth muscle hyperplasia and hypertrophy. This has been demonstrated in animal models of hypertension in which there was a reduction in blood pressure and a reduction in the growth of the smooth muscle layer. Targeting the signaling pathway that is activated by multiple receptors, including GPCRs and growth factor receptors, would reduce the need to target each receptor independently. However, inhibition of ERK would have to be targeted specifically to the vascular smooth muscle in order to prevent nonselective inhibition of cell growth elsewhere in the body. Indirect inhibitors of ERK activation could be used, and some of these are already in use therapeutically. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, for example, are used in the treatment of hypercholesterolemia. They inhibit the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol, which is also required for the production of the isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate (Figure 6). Posttranslational modification of Ras by farnesyl pyrophosphate is required to enable its translocation to the cell membrane, where it is activated. For example, simvastatin inhibits angiotensin II-stimulated ERK activation, and inhibits proliferation of human vascular smooth muscle cells by preventing the farnesylation of Ras. A question mark, however, is whether high enough concentrations of statins could be obtained in vivo to replicate the effects seen in vitro.

**Conclusion**

Hypertension is associated with increased levels of ERK activity in vascular smooth muscle. This increase in ERK activity appears to be involved in both the enhanced contractile responses and the increased smooth muscle proliferation seen in hypertension (Figure 2). This fact makes it an attractive target for treatment of hypertension as this would enable dual inhibition of both contractile responses and smooth muscle hyperplasia. A potential problem with targeting ERK would be selectively targeting the vascular smooth muscle to prevent inhibition of cell growth in other tissues in the body.

**Disclosure**

The author reports no conflicts of interest in this work.
References


